Efbemalenograstim Alfa Dosage

Usual Adult Dose for Febrile Neutropenia

20 mg subcutaneously once per chemotherapy cycle

Comments:

• This drug should NOT be administered within 14 days before and less than 24 hours after cytotoxic chemotherapy.
• This product contains natural rubber latex, which may cause allergic reactions. Individuals with latex allergies should not administer this product.
• If injecting into the abdomen, avoid a 2-inch diameter circle around the navel.

Use: This drug is indicated to reduce the risk of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs

Renal Dose Adjustments

Dose adjustment may be required; however, no specific guidelines have been suggested.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Serious allergic reactions to granulocyte stimulating factors such as efbemalenograstim alfa-vuxw, pegfilgrastim, or filgrastim products

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Before use, remove the carton from the refrigerator, keeping the prefilled syringe inside, for at least 30 minutes to allow the product to reach room temperature.
• Discard any product left at room temperature for more than 48 hours.
• Before administration, visually inspect for particulate matter and discoloration. Do not administer if discoloration or particulates are observed.
• Rotate injection sites. Do not inject into scar tissue or areas that are reddened, inflamed, or swollen.
• The manufacturer product information should be consulted.

Storage requirements:

• Store at 2C to 8C (36F to 46F), protected from light.
• Do not shake.
• Do not freeze. Discard the syringe if it is frozen.
• Syringes that have been stored at room temperature for over 48 hours should be discarded.

General:

• This drug is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Monitoring:
Cardiovascular: Capillary leak syndrome
Hematologic: Platelet counts, CBC
Oncologic: Myelodysplastic syndrome (MDS), Acute myeloid leukemia (AML)

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• Rupture or enlargement of the spleen may occur. If left upper quadrant abdominal pain or left shoulder pain occurs, report it to your healthcare provider immediately.
• Dyspnea, with or without fever, progressing to acute respiratory distress syndrome, may occur. Report dyspnea to your healthcare provider immediately.
• Serious allergic reactions may occur. Seek immediate medical attention if signs or symptoms of hypersensitivity reaction occur.
• In patients with sickle cell disease, sickle cell crisis and death have been reported with the use of human granulocyte colony-stimulating factors. Potential risks and benefits for patients with sickle cell disease should be discussed prior to the administration of this drug.
• If signs or symptoms of glomerulonephritis, aortitis, or capillary leak syndrome occur, report them to your healthcare provider immediately.
• There may be an increased risk of myelodysplastic syndrome and/or acute myeloid leukemia in patients with breast and lung cancer who receive this drug in conjunction with chemotherapy and/or radiation therapy. Report to your physician the signs and symptoms of MDS or AML.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer